Anterior segment changes on ultrasound biomicroscopy after intravitreal anti vascular endothelial growth factor injection

Medical Journal Armed Forces India

Volumn 73, Issue 1, 2017, Pages 58-64

  Trehan, H S ^a   Kaushik, Jaya ^b   Rangi, Atul ^c   Parihar, A S ^d   Vashisht, P ^a   Parihar, J K S ^e  

^a INHS Asvini   (India)

^b Classified Specialist   (India)

^c ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

^d C o Navy Office   (India)

^e Ministry of Defence Government Of India   (India)

Author keywords

Anterior chamber; Anti vascular endothelial growth factor; Intraocular pressure; Intravitreal; Ultrasound biomicroscopy

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ADULT; AGED; ANTERIOR EYE CHAMBER; ANTERIOR EYE CHAMBER ANGLE; ANTERIOR EYE SEGMENT; ARTICLE; BIOMICROSCOPY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PRESSURE MEASUREMENT; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

EID: 85009727492     PISSN: 03771237     EISSN: 22134743     Source Type: Journal    
DOI: 10.1016/j.mjafi.2016.10.007     Document Type: Article

References (19)

1. Amoaku WMK. The Royal College of Ophthalmologists interim recommendations for the management of patients with age-related macular degeneration. Eye. 2008;22 (6):864-868.
2. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859-870.
3. Ferrara N, Hillan KJ, Gerber H-P, Novotny W. Case history: discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(May (5)):391-400.
4. Wu H, Chen TC. The effects of intravitreal ophthalmic medications on intraocular pressure. Semin Ophthalmol. 2009;24(January (2)):100-105.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(October (14)):1419-1431.
6. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe's Arch Clin Exp Ophthalmol. 2007;246(August (1)): 81-87.
7. Singh RSJ, Kim JE. Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents. Drugs Aging. 2012;29(December (12)):949-956.
8. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (London). 2009;23(January (1)):181-185.
9. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology. 2006;113(July (7)):1174-1178.
10. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009;18 (December (9)):658-661.
11. Dorairaj S, Liebmann JM, Ritch R. Quantitative evaluation of anterior segment parameters in the era of imaging. Trans Am Ophthalmol Soc. 2007;105:99.
12. Tello C, Liebmann J, Potash SD, Cohen H, Ritch R. Measurement of ultrasound biomicroscopy images: intraobserver and interobserver reliability. IOVS. 1994;35 (August (9)):3549-3552.
13. Urbak SF, Pedersen JK, Thorsen TT. Ultrasound biomicroscopy. II. Intraobserver and interobserver reproducibility of measurements. Acta Ophthalmol Scand. 1998;76(October (5)):546-549.
14. Höhn F, Mirshahi A. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal Ranibizumab application. Graefes Arch Clin Exp Ophthalmol. 2010;248(October (10)):1371-1375.
15. Knecht PB, Michels S, Sturm V, Bosch MM, Menke MN. Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. Retina (Philadelphia Pa). 2009;29(September (8)): 1175-1181.
16. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27(8):1044-1047.
17. Sharei V, Höhn F, Köhler T, Hattenbach L-O, Mirshahi A. Course of intraocular pressure after intravitreal injection of 0.05 mL Ranibizumab (Lucentis). Eur J Ophthalmol. 2010;20 (February (1)):174-179.
18. Goktas A, Goktas S, Atas M, Demircan S, Yurtsever Y. Shortterm impact of intravitreal Ranibizumab injection on axial ocular dimension and intraocular pressure. Cutan Ocul Toxicol. 2013;32(1):23-26.
19. Singer MA, Groth SL, Sponsel WE, et al. Association of OCT angle recess width with IOP response after intravitreal triamcinolone injection. Retina. 2013;33(February (2)):282-286.